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Metastatic melanomapatients who were treated with patient-speciﬁc vaccines consistingof dendritic cells loaded with autologous
tumor cells had a 5-year survival of over 50%. Enzyme-linked immunospot (ELISPOT) has been used to detect antigen reactive T
cells as a means of determining immune response. We wished to determine whether IFN-gamma secretion in an ELISPOT assay
was prognostic or predictive for survival following treatment. Peripheral blood mononuclear cells (PBMCs) collected at weeks 0
and 4 were evaluated by ELISPOT assay for response to autologous tumor cells. Overall, there was slight increase in the number
of tumor reactive lymphocytes from week 0 to week 4. Using >5 spots/100K PBMC as the cutoﬀ, a log-rank analysis revealed
only a slight statistical signiﬁcance in overall survival for patients who lacked tumor reactive PBMCs at week 4. The sensitivity of
ELISPOT in the context of patient-speciﬁc cellular vaccines is unclear.
1.Introduction
Metastatic melanoma is generally considered to be incur-
able. Immunotherapy is a promising alternative treatment
to chemotherapy, but challenges remain in determining
response to therapy. Clinical trials that use adoptive
immunotherapy regimens need surrogate markers to mea-
sure responsiveness. Currently, measuring changes in the
level of serum cytokines by the enzyme-linked immunosor-
bant assay (ELISA) does not measure speciﬁc antigen
responses. A novel-cell-based immune monitoring assay like
the enzyme-linked immunosorbant spot (ELISPOT) assay
may be a more precise and quantiﬁable measure of immune
response.
Attempts to measure changes in serum cytokines
involved in immune response (i.e., IL-10 and IL-12) by
ELISA yielded no detectable levels in patients treated with
the dendritic cell-based vaccine (unpublished observations).
In light of this, we chose to use the ELISPOT assay because
it is able to measure antigen-speciﬁc responses in very small
subsets of eﬀector cell populations. Such assays have been
touted as a measure of whether a vaccine is enhancing
immunity and as possible prognostic and predictive markers
for melanoma patients receiving cancer vaccines made up
of melanoma-speciﬁc peptides such as MART-1, gp100 and
tyrosinase [1]. Cytokines that are secreted by immune cells
in response to antigenic stimulation are rapidly captured
by antibodies before they are diluted in the supernatant,
capturedbyreceptorsofothercells,ordegraded.Thecolored
spot end producttypicallyrepresentsanindividual cytokine-
producing cell that can be counted. This allows ELISPOT
assays to detect immune reactive cells that may be present
at a frequency of less than 1/100,000 peripheral blood
mononuclearcells. ELISPOT has provedtobe a reliable assay
for lymphocyte recognition of peptide antigens based on the
secretion of cytokines such as interferon gamma.
We recently observed some remarkably long periods of
progression-free survival and an encouraging 5-year survival
rate of 50%, in patients with metastatic melanoma who
were treated with patient-speciﬁc vaccines consisting of
autologous dendritic cells loaded with interferon-gamma-
treated and irradiated autologous tumor cells that had2 Journal of Biomedicine and Biotechnology
been proliferating in culture [2]. The vaccinations were
given once a week for three weeks and once a month
for ﬁve months. The cell-based vaccine was administered
in granulocyte macrophage-colony stimulating factor (GM-
CSF) and injected subcutaneously.
In this series of experiments, we used an ELISPOT
assay as a metric for postvaccination immune augmentation.
The sensitivity of such assays in the context of our clinical
trial is unclear since we were immunizing with antigens
derivedfrom tumorcells withoutawareness ofwhich tumor-
associated antigens might be most important in the immune
response. Inthis case,we couldnot useanELISPOTtetramer
assay which employs the use of speciﬁc peptide to detect
antigen speciﬁc T cells because we were not focusing on a
single speciﬁc antigen [3]. We therefore had to rely on the
release ofgamma interferon froma populationofautologous
lymphocytes based on their exposure to cryopreserved
autologous tumor cells that had been proliferating in vitro.
Wehypothesized that these cellswere the best representatives
for monitoring immune response for each patient since they
representthepatient’sowntumorcellsandsubsequentlymay
contain all of the available tumor associated antigens.
2.Materialsand Methods
2.1. Patients. Melanoma patients with recurrent or
metastatic disease were enrolled in a phase I/II clinical
trial [2]. All patients had to be oﬀ any immunosuppressive
therapy for at least 4 weeks and meet ECOG (Eastern
Cooperative Oncology Group) performance levels of 0–2 at
the time of initial treatment. At the beginning of treatment,
patients were tested for anergy to common recall antigens
using available tests for Candida, trichophyton, and mumps
but anergic patients were not denied treatment. Those
patients with brain metastases not currently receiving
pharmacologic doses of corticosteroids with therapy
controlled tumors were eligible for enrollment. A total of 54
patients were clinically evaluable but only 42 were included
in this study.
2.2. Autologous Dendritic Cell Generation. Dendritic cells
(DCs) were generated by plastic adherence method as previ-
ouslydescribed[4,5].Brieﬂy,peripheralbloodmononuclear
cells were isolated by ﬁcoll-hypaque (GE Healthcare, Buck-
inghamshire, United Kingdom) density gradient separation
from apheresis collections. The adherent populations were
then incubated in AIM-V supplemented with 1000IU/mL
each of IL-4 (CellGenix, Freiburg, Germany) and GM-CSF
(Invitrogen, Grand Island, NY) for 6 days prior to loading
with autologous tumor cells.
2.3. Autologous Tumor Cell Line Generation. Pure melanoma
tumor cell lines (deﬁned as containing less than 5% ﬁbrob-
lasts), generated using techniques previously described [6–
8], were incubated with 1000IU/mL of IFN-γ (InterMune,
Brisbane, CA) for 72 hours, irradiated with 100Gy from a
cesium source, and cryopreserved [9]. The tumor cells were
recovered from cryopreservation, washed 3x with PBS, and
then added to the in vitro cultivated DCs and incubated for
∼24 hours. The antigen loaded DC were harvested by gentle
scraping witharubberpolicemanandcryopreservedatequal
amounts in 9–11 aliquots.
2.4. Treatment Regimen. Aliquots of dendritic cells loaded
with tumor cells were thawed in a 37◦C water bath, washed
2xwith AIM-V,combinedwith 500ug/mLGM-CSFinsaline
and subcutaneously injected at weeks 1, 2, 3, 8, 12, 16, 20,
and 24. Peripheral blood mononuclear cells (PBMCs) were
obtained from peripheral blood samples at weeks 0 and 4
and were cryopreserved after separation of red blood cells by
ﬁcoll-hypaque density centrifugation.
2.5. IFN-γ Enzyme-Linked Immunospot (ELISPOT) Assay.
Using BD ELISPOT Human IFN-γ ELISPOT Kit (BD
Pharmingen, San Diego, Calif), thawed peripheral blood
mononuclear cells (PBMCs) were rested for 24 hours and
then cultured in four replicates at 2.0 × 105 viable cells
with or without 4.0 × 105 viable autologous tumor cells per
well in AIM-V in nitrocellulose backed 96 well plates. The
PBMC:ATC ratio and incubation time were chosen based
on work by Malyguine et al. [10]. Controls consisted of
PBMCs stimulated with a combined cocktail of 3000IU/mL
IL-2, 2μg/mL PHA, and 5μg/mL OKT3 as a positive control,
PBMCs or tumor cells only and AIM-V medium only
as background and negative controls, respectively. After
48 hour incubation, plates were washed and stained as
per manufacturer’s instructions. Brieﬂy, plates were washed
twice with 200μL/well deionized water and then three times
with 200μL/well Wash Buﬀer (provided by kit). 100μL/well
of1μg/mL mouse antihuman IFN-γ-biotinylated mAb (pro-
vided by kit) in assay diluent was added and the plates
were incubated for 2 hours at room temperature. The plates
were then rinsed, incubated with streptavidin-HRP solution
for 1 hour and developed with aminoethylcarbazole (AEC)
peroxidase substrate solution provided with the kits. The
plates were then counted on an ImmunoSpot instrument
(Cellular Technology Ltd. Cleveland, Ohio).
2.6. Statistical Analysis. Signiﬁcant diﬀerences were deﬁned
by P-value ≤.05 using Student’s t-test of two-tailed, two
samples of equal variance. Log-rank calculations were used
to determine whether there was a signiﬁcant diﬀerence in
survival curves. Progression-free and overall survival times
were determined by time in months from ﬁrst injection to
last followup or patient expiration.
3.Results
The detection of antigen-speciﬁc peripheral blood T
lymphocytes was determined by IFN-γ Enzyme-linked
Immunospot (ELISPOT) assay using autologous tumor cells
as the antigen source. Controls consisted of PBMC only
(unstimulated), PBMCs exposed to a cytokine cocktail to
induce the expression of IFN-γ (nonspeciﬁc stimulation),
tumor cells only or media only (Figure 1). Neither the
tumor cell only nor media controls resulted in any spottingJournal of Biomedicine and Biotechnology 3
Table 1: Signiﬁcant changes in tumor reactive T cells as measured
by ELISPOT in patients receiving DC-based immunotherapy for
metastatic melanoma.
Change in relative number of spots Week 4 versus week 0
(N = 42)
Increase P ≤ .05 7 (16.6%)
Decrease P ≤ .05 4 (9.5%)
No change P ≥ .05 31 (73.8%)
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Figure 1: Peripheral blood lymphocytes were placed in the wells of
ELISPOT plates in quadruplicate under three separate conditions:
unstimulated (−Stm), stimulated with 3000IU/mL IL-2, 2μg/mL
PHA, and 5μg/mL OKT3 (+Stm), or combined with autologous
tumor cells at a ratio of 1:2 (+ATC). After 48 hours, IFN-
γ secretion was determined as per manufacturer’s instructions.
Numbers indicate spots counted by automated counter.
activity in all wells examined (data not shown). The levels of
ELISPOT spotting were adjusted for nonspeciﬁc (unstimu-
lated)IFN-γ secreting lymphocytesandtheresults areshown
in Figure 2.
Out of 54 patients treated on the vaccine study, 42
were evaluable at weeks 0 and 4 for the ELISPOT testing.
Although there was no signiﬁcant change in the average
number of tumor reactive PBMCs by week 4, there was
trend toward slightly higher frequencies (week 0: 27.1 ±
6.9 spots/100K and week 4: 30.9 ± 7.4 spots/100K, P =
.708).Only 7/42(16.6%)demonstrated a signiﬁcant increase
(P ≤ .05) in tumor reactive lymphocytes at week 4 versus
week 0. Additionally, 4/42 (9.5%) demonstrated a signiﬁcant
decrease in tumor reactive lymphocytes at week 4 versus
week 0 (Table 1). No correlations could be made with
progression-free or overall survival in either group with
signiﬁcant changes in the number of spots between week 0
and week 4 either increasing or decreasing (data not shown).
Moodie et al. reported that an acceptable ELISPOT
signal-to-noise ratio of 2:1 to3:1 results in a detection limit
of 4 to 6 spots/1 × 105 PBMC, respectively, for determining
response to the applied antigen [11]. We applied this
methodology to our assay and adjusted for any background
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Figure 2: Results of induction of IFN-γ secreting T lymphocytes
detected by ELISPOT in response to autologous tumors cells
after DC-based immunotherapy for melanoma. Peripheral blood
lymphocytes collected (PBMC) at week 0 (open bars) and week 4
(ﬁlled bars) were coincubated with puriﬁed autologous tumor cells
at a ratio of 1:2, respectively, and incubated for 48 hours. Data
shown is sorted by average number of spots/100K PMBC ± SD.
Dashed line approximates the 5spots/100K PBMC threshold.
by subtracting the activity of the nonstimulated PBMCs
(Figure 2). At week 0 or baseline, 20/42 (47.6%) showed
a signiﬁcant number of spots (>5s p o t s / 1× 105 PBMC)
in response to ATC. A similar result was seen at week 4,
with 20/42 (47.6%) patients demonstrating response to their
autologous tumor cells. Many of the same patients had
measurable responses at both weeks (17/20).
Patients were then divided into two cohorts based upon
whether they demonstrated greater than or less than 5 spots
per 100,000 PBMC in response to autologous tumor cells as
means of deﬁning responders versus nonresponders at that
timeintheirtreatmentschedule.Table2describesthepatient
clinical characteristics at the time of treatment for these
cohorts. Log-rank tests were calculated and Kaplan-Meier
plots generated for progression-free and overall survival
at either week 0 or week 4. Baseline activity of tumor
reactive lymphocytes at week 0 failed to correspond to either
progression-free or overall survival. But at week 4, tumor
reactivity correlated unfavorably to overall survival but was
not associated with progression-free survival (Figure 3). A
log-rank comparison of the 17 patients that had sustained
tumor reactive lymphocytes (>5 spots/100K PBMC at both
week 0 and week 4) did not indicate an association with
progression-free or overall survival (P = .177 and P = .156,
resp.).
Although it appears that patients in the >5spots/100K
PBMChadsigniﬁcantlyhigherlactosedehydrogenase(LDH)
serum values at both week 0 and week 4 (Table 2), no
signiﬁcant correlation to clinical performance was found
based solely on LDH values (P = .197 and P = .263,
PFS and OS, resp.). Additionally, the number of ECOG 1
and 2 patients in the >5 spots/100K PBMC is higher (8
versus 4 in the <5spots/100K PBMC group) which may
inﬂuence the survival results since it was noted that patients
who have higher ECOG scores tend to not perform as well
clinically.4 Journal of Biomedicine and Biotechnology
Table 2: Comparison of patient characteristics in the two cohorts with ELISPOT results less than or greater than 5spots/100K PBMC in
response to autologous tumor cells at week 0 and week 4 after receiving dendritic-cell-based antimelanoma therapy.
All Week 0 (<5 spots) Week 0 (>5 spots) Week 4 (<5 spots) Week 4 (>5s p o t s )
Sex M 2 6 1 41 21 51 1
F 1 6 8879
Age (years) 49.3 ± 14.1 46.0 ± 14.8 52.9 ± 12.8 46.7 ± 14.3 52.0 ± 13.8
Disease status M 1 a / b 2 0 71 371 3
M 1 c 2 2 1 571 57
A n e r g y 1 1 6565
Prior treatment
R T 6 3333
C h e m o 1 2 6657
I L - 2 1 0 7364
I F N - a l p h a 1 5 9687
G M - C S F 1 8 9999
V a c c i n e 6 3333
B C G 2 1102
m A b 1 1010
B i o c h e m o 1 6 1 151 15
DC phenotype
% CD80 38.6 ± 15.1 33.5 ± 15.2 44.4 ± 13.1 34.9 ± 14.7 42.8 ± 14.8
% CD83 10.9 ± 7.4 12.2 ± 7.0 9.5 ± 7.7 12.5 ± 7.1 9.1 ± 7.5
% CD86 82.5 ± 9.3 78.1 ± 13.5 69.6 ± 19.6 77.3 ± 13.0 70.4 ± 20.3
% CD11c 90.6 ± 7.3 89.3 ± 7.9 92.0 ± 6.4 88.8 ± 7.7 92.7 ± 6.3
Doses 1–3 Cell no. × 106 16.3 ± 7.0 16.2 ± 6.8 16.4 ± 7.2 16.1 ± 7.2 16.4 ± 6.7
% Viability 80.4 ± 9.6 79.0 ± 9.6 82.0 ± 9.1 81.0 ± 9.6 79.8 ± 9.8
DTH D T H + ( w e e k 0 ) 0 0000
DTH+ (week 4) 4 (2 eqv) 2 (2 eqv) 2 1 (1 eqv) 3
ECOG status
0 3 0 1 81 21 81 2
1 1 0 3737
2 2 1111
serum LDH (ng/mL) LDH (week 0) 578.6 ± 391.3 453.2 ± 93.7 716.6∗± 531.4 487.6 ± 162.3 678.7 ± 530.2
LDH (week 4) 594.6 ± 504.9 441.7 ± 92.9 762.9∗± 695.5 496.1 ± 321.6 703.1∗± 642.0
Each value is average ± SD where applicable. M1a: distant skin, lymph nodes, M1b: lung, and M1c: brain, liver or other visceral organs. RT: radiotherapy,
Chemo:chemotherapy(temodar,cisplatin,vinblasin,tamoxifen,etc.),Vaccine:allogeneictumorcell/lysateor peptidevaccines,BCG:bacilluscalmetteguerin,
mAb:MDX-010, Biochemo:IL-2 ± IFN pluschemotherapy,DTH: delayedtypehypersensitivity,eqv: equivocalresult,LDH: lactosedehydrogenase. ∗P ≤ .05
compared to <5spots/100K PBMC.
4.Discussion
Attempts to ﬁnd a reliable surrogate for monitoring of
immune response during the course of immune-based ther-
apies for cancer continues to be a challenge. The generation
of cytotoxic T lymphocytes (CTL) can be used as a measure
of the eﬀectiveness of antigen presentation by dendritic cells,
but only in a minority of cases does antigen-speciﬁc CTL
activity correlate with clinical outcome [12].
The ELISPOT assay is a convenient method to mon-
itor immune response since the cells used in the assay
can be cryopreserved during the course of treatment and
assayed together at a later date thus avoiding plate-to-
plate variability. Samples handled in this way, proved to
be reliably accurate and there appeared to be no adverse
functional eﬀects on the peripheral blood lymphocytes due
to cryopreservation as previously reported [13]. The use of
whole tumor cells as the antigen source, even at signiﬁcantly
high concentration (4 × 105/well), did not contribute to
signiﬁcant backgroundin the ELISPOT assay, indicating that
even a heterogeneous population of autologous tumor cells
can be used in this assay.
Other investigators have reported immune responses
in the context of ELISPOT assays which correlated with
either disease-free survival or overall survival [1, 14]b u t
in those cases, the antigens used to induce immunity were
speciﬁc peptides plus GM-CSF without dendritic cells. In
studies that have involved the use of dendritic cells, the
correlation between ELISPOT results and survival have been
mixed [15] and only a few reports have been published
that use autologous tumor cells as the antigen source to
measure immune recognition which were found not to
correspond to outcome [16]. In addition, the extent of
disease burden of patients enrolled in a study in whichJournal of Biomedicine and Biotechnology 5
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Figure 3: The induction of IFN-γ secreting lymphocytes in response to autologous tumor cells and correlation to either progression-free or
overall survival at either week 0 or week 4. Patient cohorts were grouped according to whether they had an average of greater than (>)o r
less than (<) 5spots/100K PBMC per well observed at week 0 and week 4. Sample sizes: Week 0, N = 20 for >5s p o t s / w e l la n d2 2f o r<5
spots/well, and for week 4, N = 20 for >5spots/welland22for<5spots/well. Log-rank testing was used to determine P values.
immune monitoring was conducted was also a contributing
factor in measurable responses. Patients with heavy disease
burden were reported to be less responsive immunologically
to therapy [17]. However, in our study it appeared that
many of the patients who had a higher ECOG performance
scores (ECOG 1 or 2) retained their ability to respond to
their autologous tumors cells. It should be noted however
that patients in this study group with ECOG scores of 1
or 2 had signiﬁcantly lower progression-free and overall
survival than those who had ECOG scores of 0 (P = .002
and .001, resp.). This contribution may explain why there
appears to be a signiﬁcant diﬀerence in overall survival in
patients who have >5spots/100K PBMC as indicated in
Figure 3.
However, the observation of the correlation of lack of
response to autologous tumor cells and improved overall
survival is counter intuitive. The reason for that observation
remains unclear but a recent publication by our laboratory
showed a relationship between the induction of apoptosis
in response to interferon-gamma by tumor cells and poorer
clinical performance [18]. The use of apoptotic cells in
immunotherapy has been associated with the induction of
tolerance in some cases [19]. It is possible that patients
who responded to their autologous tumor cells by releas-
ing interferon-gamma in the ELISPOT assay may also be
inducing tolerance in situ (i.e., at the site of disease).
Tumor inﬁltrating lymphocytes encountering tumor cells
may be releasing interferon-gamma which in turn induces
tolerance through apoptosis of tumor cells and phagocytosis
of resident dendritic cells.
Overall, the results are in line with previous reports
dealing with complex immune responses but further inves-
tigations will be necessary to determine what immune
monitoring assay can be employed in this setting.6 Journal of Biomedicine and Biotechnology
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